Skip to main content

Table 2 Prevalence of clinical and immunological criterion of Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria in 122 cSLE cases and 89 controls, at baseline/first visit and 1-year-follow-up

From: Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus

Criterion Cases Controls P value Cases Controls P value
Baseline/First visit Baseline/First visit 1-year follow-up 1-year follow-up
n (%) n (%) n (%) n (%)
Acute cutaneous lupus 60 (49.2) 22 (24.7) <  0.001 80 (65.6) 30 (33.7) <  0.001
 Malar rash 45 (36.9) 17 (19.1) 0.006 64 (52.5) 26 (29.2) 0.001
 Photosensitive lupus rash 29 (23.8) 14 (15.7) 0.169 34 (27.9) 16 (18.0) 0.104
 Subacute cutaneous lupus 18 (14.8) 1 (1.1) < 0.001 21 (17.2) 1 (1.1) <  0.001
Chronic cutaneous lupus 13 (10.7) 1 (1.1) 0.005 16 (13.1) 1 (1.1) 0.001
 Discoid rash 13 (10.7) 1 (1.1) 0.005 15 (12.3) 1 (1.1) 0.003
Oral ulcers 44 (36.1) 11 (12.4) <  0.001 64 (52.5) 12 (13.5) <  0.001
Alopecia 52 (42.6) 12 (6.8) <  0.001 54 (44.3) 14 (9.1) <  0.001
Synovitis 96 (78.7) 59 (66.3) 0.058 107 (87.7) 65 (73.0) 0.011
Serositis 30 (24.6) 3 (3.4) <  0.001 41 (33.6) 4 (4.5) <  0.001
 Pleuritis 22 (18.0) 2 (2.3) <  0.001 32 (26.2) 3 (3.4) <  0.001
 Pericarditis 8 (6.6) 0 0.022 9 (7.4) 2 (2.3) 0.124
Renal disorder 33 (27.0) 1 (1.1) <  0.001 49 (40.2) 2 (2.3) <  0.001
 Proteinuria 33 (27.0) 1 (1.1) <  0.001 49 (40.2) 2 (2.3) <  0.001
 Red blood cell casts 10 (8.2) 0 <  0.001 15 (12.3) 1 (1.1) <  0.001
Neuropsychiatric 10 (8.2) 1 (1.1) 0.027 23 (18.9) 1 (1.1) <  0.001
 Seizures 5 (4.1) 0 0.075 17 (13.9) 0 <  0.001
 Psychosis 2 (1.6) 0 0.510 6 (4.9) 0 0.041
 Myelitis 1 (0.8) 0 0.999 3 (2.5) 0 0.265
 Confusional state 1 (0.8) 0 0.999 1 (0.8) 0 0.999
Hemolytic anemia 44 (36.1) 4 (4.5) <  0.001 61 (50.0) 4 (4.5) <  0.001
Leukopenia/lymphopenia 39 (32.0) (10.1) <  0.001 53 (43.4) 11 (12.4) <  0.001
Thrombocytopenia 18 (14.8) 4 (4.5) 0.021 20 (16.4) 4 (4.5) 0.008
Anti-dsDNA 46 (37.7) 4 (4.5) <  0.001 65 (53.3) 5 (5.6) <  0.001
Anti-Sm 29 (23.8) 5 (5.6) <  0.001 38 (31.1) 5 (5.6) <  0.001
Antiphospholipid 30 (24.6) 5 (5.6) <  0.001 38 (31.1) 4 (4.5) <  0.001
 Anticardiolipin IgM 11 (9.0) 2 (2.3) 0.047 12 (9.8) 2 (2.3) 0.046
 Anticardiolipin IgG 23 (18.9) 2 (2.3) <  0.001 27 (22.1) 3 (2.5) <  0.001
 Lupus anticoagulant 6 (4.9) 5 (5.6) 0.999 8 (6.6) 5 (5.6) 0.999
 Anti-β2 GPI I IgM 3/61 (4.9) 1/42 (2.4) 0.644 3/61(4.9) 1/42(2.4) 0.644
 Anti- β2 GPI I IgG 3/61 (4.9) 2/42 (4.9) 0.999 3/61(4.9) 2/42(4.9) 0.999
 False-positive VDRL 4 (3.3) 1 (1.1) 0.4 4 (3.3) 1 (1.1) 0.4
Low complement 69 (56.6) 4 (4.5) <  0.001 74 (60.7) 5 (5.6) <  0.001
Direct Coombs test 34 (27.9) 6 (6.7) <  0.001 38 (31.1) 6 (6.7) <  0.001
  1. The Pearson chi-square test analyzed differences between proportions, and the difference was regarded as statistically significant when p < 0.05
  2. No patients had toxic epidermal necrolysis, hypertrophic lupus, mucosal lupus, lupus tumidus, and chilblains lupus. One cSLE case had bullous lupus, another one cSLE had panniculitis, and one control had mononeuritis multiplex at 1-year-follow-up. Anti-β2 glycoprotein-I IgM and IgG were tested in 61/122 (50%) cSLE cases and 42/89 (47.2%) controls, at baseline/first visit and 1-year-follow-up